Excitingly, the noncovalent and selective inhibitors also demonstrated selective killing of p53-null tumor cells with disruption of cell energy metabolism (Chen et al., 2021b) (see review (Fiume et al., 2015)). This evidence concerns the gene TP53 and neoplasm.